Published in J Med Chem on September 13, 2001
Architecture of P2Y nucleotide receptors: structural comparison based on sequence analysis, mutagenesis, and homology modeling. J Med Chem (2004) 2.15
2-Substitution of adenine nucleotide analogues containing a bicyclo[3.1.0]hexane ring system locked in a northern conformation: enhanced potency as P2Y1 receptor antagonists. J Med Chem (2003) 1.57
Distinct spatio-temporal Ca2+ signaling elicited by integrin alpha2beta1 and glycoprotein VI under flow. Blood (2009) 1.57
2-Chloro N(6)-methyl-(N)-methanocarba-2'-deoxyadenosine-3',5'-bisphosphate is a selective high affinity P2Y(1) receptor antagonist. Br J Pharmacol (2002) 1.52
Quantitation of the P2Y(1) receptor with a high affinity radiolabeled antagonist. Mol Pharmacol (2002) 1.49
On the applicability of GPCR homology models to computer-aided drug discovery: a comparison between in silico and crystal structures of the beta2-adrenergic receptor. J Med Chem (2008) 1.46
Induction of novel agonist selectivity for the ADP-activated P2Y1 receptor versus the ADP-activated P2Y12 and P2Y13 receptors by conformational constraint of an ADP analog. J Pharmacol Exp Ther (2004) 1.31
Third-generation immucillins: syntheses and bioactivities of acyclic immucillin inhibitors of human purine nucleoside phosphorylase. J Med Chem (2009) 1.29
The crystallographic model of rhodopsin and its use in studies of other G protein-coupled receptors. Annu Rev Biophys Biomol Struct (2003) 1.27
Antiaggregatory activity in human platelets of potent antagonists of the P2Y 1 receptor. Biochem Pharmacol (2004) 1.25
Neoceptor concept based on molecular complementarity in GPCRs: a mutant adenosine A(3) receptor with selectively enhanced affinity for amine-modified nucleosides. J Med Chem (2001) 1.21
P2Y(1) receptors mediate inhibitory neuromuscular transmission in the rat colon. Br J Pharmacol (2009) 1.10
[32P]2-iodo-N6-methyl-(N)-methanocarba-2'-deoxyadenosine-3',5'-bisphosphate ([32P]MRS2500), a novel radioligand for quantification of native P2Y1 receptors. Br J Pharmacol (2006) 1.07
Molecular recognition at purine and pyrimidine nucleotide (P2) receptors. Curr Top Med Chem (2004) 1.06
Nucleotide analogues containing 2-oxa-bicyclo[2.2.1]heptane and l-alpha-threofuranosyl ring systems: interactions with P2Y receptors. Bioorg Med Chem (2004) 1.04
Defining the nucleotide binding sites of P2Y receptors using rhodopsin-based homology modeling. J Comput Aided Mol Des (2006) 1.01
Development of selective high affinity antagonists, agonists, and radioligands for the P2Y1 receptor. Comb Chem High Throughput Screen (2008) 0.86
Molecular recognition at adenine nucleotide (P2) receptors in platelets. Semin Thromb Hemost (2005) 0.84
Molecular modeling of the human P2Y14 receptor: A template for structure-based design of selective agonist ligands. Bioorg Med Chem (2015) 0.82
Design and synthesis of new bicyclic diketopiperazines as scaffolds for receptor probes of structurally diverse functionality. Org Biomol Chem (2005) 0.78
New highly active antiplatelet agents with dual specificity for platelet P2Y1 and P2Y12 adenosine diphosphate receptors. Eur J Med Chem (2015) 0.78
Design and Synthesis of Fluorescent Acyclic Nucleoside Phosphonates as Potent Inhibitors of Bacterial Adenylate Cyclases. ChemMedChem (2016) 0.75
International Union of Pharmacology. XXV. Nomenclature and classification of adenosine receptors. Pharmacol Rev (2001) 9.90
Nomenclature and classification of purinoceptors. Pharmacol Rev (1994) 5.32
Direct observation of brownian motion of lipids in a membrane. Proc Natl Acad Sci U S A (1991) 3.91
Diffusion of injected macromolecules within the cytoplasm of living cells. Proc Natl Acad Sci U S A (1981) 3.61
Constitutive release of ATP and evidence for major contribution of ecto-nucleotide pyrophosphatase and nucleoside diphosphokinase to extracellular nucleotide concentrations. J Biol Chem (2000) 2.86
Molecular pathogenesis of cholestasis. N Engl J Med (1998) 2.68
125I-4-aminobenzyl-5'-N-methylcarboxamidoadenosine, a high affinity radioligand for the rat A3 adenosine receptor. Mol Pharmacol (1994) 2.65
Agonist-induced desensitization of the beta-adrenergic receptor-linked adenylate cyclase. Pharmacol Rev (1983) 2.62
Functionalized congeners of 1,3-dialkylxanthines: preparation of analogues with high affinity for adenosine receptors. J Med Chem (1985) 2.52
Structural mosaicism on the submicron scale in the plasma membrane. Biophys J (1998) 2.50
The Concise Guide to PHARMACOLOGY 2013/14: overview. Br J Pharmacol (2013) 2.48
Structural and functional polarity of canalicular and basolateral plasma membrane vesicles isolated in high yield from rat liver. J Cell Biol (1984) 2.47
Unconfined lateral diffusion and an estimate of pericellular matrix viscosity revealed by measuring the mobility of gold-tagged lipids. J Cell Biol (1993) 2.47
Adenosine A3 receptor stimulation and cerebral ischemia. Eur J Pharmacol (1994) 2.33
Kinetics of activation of phospholipase C by P2Y purinergic receptor agonists and guanine nucleotides. J Biol Chem (1989) 2.23
Spatial Fourier analysis of video photobleaching measurements. Principles and optimization. Biophys J (1991) 2.13
Second messenger cascade specificity and pharmacological selectivity of the human P2Y1-purinoceptor. Br J Pharmacol (1996) 2.12
Functionalized congeners of adenosine: preparation of analogues with high affinity for A1-adenosine receptors. J Med Chem (1985) 2.12
Identification of competitive antagonists of the P2Y1 receptor. Mol Pharmacol (1996) 2.10
2-Substitution of N6-benzyladenosine-5'-uronamides enhances selectivity for A3 adenosine receptors. J Med Chem (1994) 2.10
Towards a revised nomenclature for P1 and P2 receptors. Trends Pharmacol Sci (1997) 2.09
Evidence that UTP and ATP regulate phospholipase C through a common extracellular 5'-nucleotide receptor in human airway epithelial cells. Mol Pharmacol (1991) 2.00
Direct demonstration of mechanically induced release of cellular UTP and its implication for uridine nucleotide receptor activation. J Biol Chem (1997) 1.99
Catecholamine-specific desensitization of adenylate cyclase. Evidence for a multistep process. J Biol Chem (1980) 1.95
Comparative biochemistry of non-muscle actins. J Biol Chem (1977) 1.92
Site-directed mutagenesis identifies residues involved in ligand recognition in the human A2a adenosine receptor. J Biol Chem (1995) 1.92
Outpatient liver biopsy: how safe is it? Ann Intern Med (1993) 1.90
Phosphoinositide hydrolysis by guanosine 5'-[gamma-thio]triphosphate-activated phospholipase C of turkey erythrocyte membranes. Biochem J (1988) 1.88
A binding site model and structure-activity relationships for the rat A3 adenosine receptor. Mol Pharmacol (1994) 1.87
[3H]xanthine amine congener of 1,3-dipropyl-8-phenylxanthine: an antagonist radioligand for adenosine receptors. Proc Natl Acad Sci U S A (1986) 1.85
Synthesis, biological activity, and molecular modeling of ribose-modified deoxyadenosine bisphosphate analogues as P2Y(1) receptor ligands. J Med Chem (2000) 1.85
P2-purinergic receptors: subtype-associated signaling responses and structure. Annu Rev Pharmacol Toxicol (1995) 1.84
Identification of potent, selective P2Y-purinoceptor agonists: structure-activity relationships for 2-thioether derivatives of adenosine 5'-triphosphate. J Med Chem (1993) 1.84
The rat canalicular conjugate export pump (Mrp2) is down-regulated in intrahepatic and obstructive cholestasis. Gastroenterology (1997) 1.83
Pertussis toxin does not inhibit muscarinic-receptor-mediated phosphoinositide hydrolysis or calcium mobilization. Biochem J (1985) 1.83
Epidermal growth factor stimulates the rapid accumulation of inositol (1,4,5)-trisphosphate and a rise in cytosolic calcium mobilized from intracellular stores in A431 cells. J Biol Chem (1987) 1.82
Pharmacological selectivity of the cloned human P2U-purinoceptor: potent activation by diadenosine tetraphosphate. Br J Pharmacol (1995) 1.81
Competitive and selective antagonism of P2Y1 receptors by N6-methyl 2'-deoxyadenosine 3',5'-bisphosphate. Br J Pharmacol (1998) 1.80
Differential effects of P2-purinoceptor antagonists on phospholipase C- and adenylyl cyclase-coupled P2Y-purinoceptors. Br J Pharmacol (1994) 1.77
Isolated rat hepatocyte couplets: a primary secretory unit for electrophysiologic studies of bile secretory function. Proc Natl Acad Sci U S A (1984) 1.77
Expression of a cloned P2Y purinergic receptor that couples to phospholipase C. Mol Pharmacol (1994) 1.76
Peliosis hepatis associated with androgenic-anabolic steroid therapy. A severe form of hepatic injury. Ann Intern Med (1974) 1.75
Agonist action of adenosine triphosphates at the human P2Y1 receptor. Mol Pharmacol (1998) 1.74
Mechanisms and regulation of bile secretion. Hepatology (1991) 1.74
Dissection of the human acetylcholinesterase active center determinants of substrate specificity. Identification of residues constituting the anionic site, the hydrophobic site, and the acyl pocket. J Biol Chem (1993) 1.72
The prognostic importance of clinical and histologic features in asymptomatic and symptomatic primary biliary cirrhosis. N Engl J Med (1983) 1.67
Role of the extracellular loops of G protein-coupled receptors in ligand recognition: a molecular modeling study of the human P2Y1 receptor. Biochemistry (1999) 1.64
A mutational analysis of residues essential for ligand recognition at the human P2Y1 receptor. Mol Pharmacol (1997) 1.63
A physiological role of the adenosine A3 receptor: sustained cardioprotection. Proc Natl Acad Sci U S A (1998) 1.63
Adenosine A1 and A2 receptors: structure--function relationships. Med Res Rev (1992) 1.62
Quantitation of extracellular UTP using a sensitive enzymatic assay. Br J Pharmacol (1999) 1.61
Deoxyadenosine bisphosphate derivatives as potent antagonists at P2Y1 receptors. J Med Chem (1998) 1.61
Human P2Y1 receptor: molecular modeling and site-directed mutagenesis as tools to identify agonist and antagonist recognition sites. J Med Chem (1998) 1.61
HEK293 human embryonic kidney cells endogenously express the P2Y1 and P2Y2 receptors. Neuropharmacology (1997) 1.59
Hepatic injury from chronic hypervitaminosis a resulting in portal hypertension and ascites. N Engl J Med (1974) 1.58
Exercise therapy in hypertensive men. JAMA (1970) 1.58
A2A adenosine receptors from rat striatum and rat pheochromocytoma PC12 cells: characterization with radioligand binding and by activation of adenylate cyclase. Mol Pharmacol (1992) 1.57
Direct preconditioning of cultured chick ventricular myocytes. Novel functions of cardiac adenosine A2a and A3 receptors. J Clin Invest (1996) 1.57
Caspase-3 controls both cytoplasmic and nuclear events associated with Fas-mediated apoptosis in vivo. Proc Natl Acad Sci U S A (1998) 1.56
Crystal structures of aged phosphonylated acetylcholinesterase: nerve agent reaction products at the atomic level. Biochemistry (1999) 1.55
A functionalized congener approach to adenosine receptor antagonists: amino acid conjugates of 1,3-dipropylxanthine. Mol Pharmacol (1986) 1.55
Cytochemical localization of Na+, K+-ATPase in the rat hepatocyte. J Clin Invest (1978) 1.54
Glutamate residues in the second extracellular loop of the human A2a adenosine receptor are required for ligand recognition. Mol Pharmacol (1996) 1.54
The role of amino acids in extracellular loops of the human P2Y1 receptor in surface expression and activation processes. J Biol Chem (1999) 1.54
Probing the adenosine receptor with adenosine and xanthine biotin conjugates. FEBS Lett (1985) 1.52
Idiopathic portal hypertension. Comparison with the portal hypertension of cirrhosis and extrahepatic portal vein obstruction. Ann Intern Med (1967) 1.51
Mutagenesis reveals structure-activity parallels between human A2A adenosine receptors and biogenic amine G protein-coupled receptors. J Med Chem (1997) 1.51
Effect of UDCA on intracellular and biliary pH in isolated rat hepatocyte couplets and perfused livers. Am J Physiol (1991) 1.51
Direct measurement of lateral transport in membranes by using time-resolved spatial photometry. Proc Natl Acad Sci U S A (1985) 1.51
Identification of the A2 adenosine receptor binding subunit by photoaffinity crosslinking. Proc Natl Acad Sci U S A (1989) 1.50
Pattern of necrosis in acute viral hepatitis. Prognostic value of bridging (subacute hepatic necrosis). N Engl J Med (1970) 1.50
Structures of recombinant native and E202Q mutant human acetylcholinesterase complexed with the snake-venom toxin fasciculin-II. Acta Crystallogr D Biol Crystallogr (2000) 1.47
Differential modification of the interaction of cardiac muscarinic cholinergic and beta-adrenergic receptors with a guanine nucleotide binding component(s). Mol Pharmacol (1982) 1.47
Molecular probes for extracellular adenosine receptors. Biochem Pharmacol (1987) 1.47
Improved survival with primary sclerosing cholangitis. A review of clinicopathologic features and comparison of symptomatic and asymptomatic patients. Gastroenterology (1987) 1.45
Apparent affinity of some 8-phenyl-substituted xanthines at adenosine receptors in guinea-pig aorta and atria. Br J Pharmacol (1987) 1.45
ATP, an agonist at the rat P2Y(4) receptor, is an antagonist at the human P2Y(4) receptor. Mol Pharmacol (2000) 1.44
Anilide derivatives of an 8-phenylxanthine carboxylic congener are highly potent and selective antagonists at human A(2B) adenosine receptors. J Med Chem (2000) 1.44
Canalicular bile formation in the isolated perfused rat liver. Am J Physiol (1971) 1.43
Substrate inhibition of acetylcholinesterase: residues affecting signal transduction from the surface to the catalytic center. EMBO J (1992) 1.43
Distinct pathways of desensitization of A1- and A2-adenosine receptors in DDT1 MF-2 cells. Mol Pharmacol (1991) 1.42